APA (7th ed.) Citation

JA, Z., JR, S., CD, E., ESM, N., H, W., AM, W., . . . MA, M. (2026). Donanemab in early symptomatic Alzheimer's disease: Results from the TRAILBLAZER-ALZ 2 long-term extension. The journal of prevention of Alzheimer's disease, 13(2), 100446. https://doi.org/10.1016/j.tjpad.2025.100446

Chicago Style (17th ed.) Citation

JA, Zimmer, et al. "Donanemab in Early Symptomatic Alzheimer's Disease: Results from the TRAILBLAZER-ALZ 2 Long-term Extension." The Journal of Prevention of Alzheimer's Disease 13, no. 2 (2026): 100446. https://doi.org/10.1016/j.tjpad.2025.100446.

MLA (9th ed.) Citation

JA, Zimmer, et al. "Donanemab in Early Symptomatic Alzheimer's Disease: Results from the TRAILBLAZER-ALZ 2 Long-term Extension." The Journal of Prevention of Alzheimer's Disease, vol. 13, no. 2, 2026, p. 100446, https://doi.org/10.1016/j.tjpad.2025.100446.